{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:49:41Z","timestamp":1787064581106,"version":"build-2736575974"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:00:00Z","timestamp":1640908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC 8\/2019"],"award-info":[{"award-number":["FFC 8\/2019"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza Universit\u00e0 di Roma","doi-asserted-by":"publisher","award":["RM11916B6A28725C"],"award-info":[{"award-number":["RM11916B6A28725C"]}],"id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutations in the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) protein lead to persistent lung bacterial infections, mainly due to\n                    <jats:italic>Pseudomonas aeruginosa,<\/jats:italic>\n                    causing loss of respiratory function and finally death of people affected by CF. Unfortunately, even in the era of CFTR modulation therapies, management of pulmonary infections in CF remains highly challenging especially for patients with advanced stages of lung disease. Recently, we identified antimicrobial peptides (AMPs), namely Esc peptides, with potent antipseudomonal activity. In this study, by means of electrophysiological techniques and computational studies we discovered their ability to increase the CFTR-controlled ion currents, by direct interaction with the F508del-CFTR mutant. Remarkably, this property was not explored previously with any AMPs or peptides in general. More interestingly, in contrast with clinically used CFTR modulators, Esc peptides would give particular benefit to CF patients by combining their capability to eradicate lung infections and to act as promoters of airway wound repair with their ability to ameliorate the activity of the channel with conductance defects. Overall, our findings not only highlighted Esc peptides as the first characterized AMPs with a novel property, that is the potentiator activity of CFTR, but also paved the avenue to investigate the functions of AMPs and\/or other peptide molecules, for a new up-and-coming pharmacological approach to address CF lung disease.\n                  <\/jats:p>","DOI":"10.1007\/s00018-021-04030-2","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T00:02:24Z","timestamp":1640908944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Esc peptides as novel potentiators of defective cystic fibrosis transmembrane conductance regulator: an unprecedented property of antimicrobial peptides"],"prefix":"10.1007","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0528-1158","authenticated-orcid":false,"given":"Loretta","family":"Ferrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3423-8474","authenticated-orcid":false,"given":"Floriana","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5040-5688","authenticated-orcid":false,"given":"Maria Rosa","family":"Loffredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1295-1084","authenticated-orcid":false,"given":"Bruno","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8707-4333","authenticated-orcid":false,"given":"Bruno","family":"Botta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8686-3461","authenticated-orcid":false,"given":"Luis J. V.","family":"Galietta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-1254","authenticated-orcid":false,"given":"Mattia","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5991-5868","authenticated-orcid":false,"given":"Maria Luisa","family":"Mangoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,31]]},"reference":[{"issue":"1","key":"4030_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/j.1476-5381.2010.01137.x","volume":"163","author":"AW Cuthbert","year":"2011","unstructured":"Cuthbert AW (2011) New horizons in the treatment of cystic fibrosis. Br J Pharmacol 163(1):173\u2013183. https:\/\/doi.org\/10.1111\/j.1476-5381.2010.01137.x","journal-title":"Br J Pharmacol"},{"issue":"1","key":"4030_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2017.02.024","volume":"169","author":"F Liu","year":"2017","unstructured":"Liu F, Zhang Z, Csanady L, Gadsby DC, Chen J (2017) Molecular structure of the human CFTR ion channel. Cell 169(1):85-95 e88. https:\/\/doi.org\/10.1016\/j.cell.2017.02.024","journal-title":"Cell"},{"issue":"1","key":"4030_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1152\/physrev.00007.2018","volume":"99","author":"L Csanady","year":"2019","unstructured":"Csanady L, Vergani P, Gadsby DC (2019) Structure, gating, and regulation of the Cftr anion channel. Physiol Rev 99(1):707\u2013738. https:\/\/doi.org\/10.1152\/physrev.00007.2018","journal-title":"Physiol Rev"},{"issue":"1 Suppl","key":"4030_CR4","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1152\/physrev.1999.79.1.S23","volume":"79","author":"DN Sheppard","year":"1999","unstructured":"Sheppard DN, Welsh MJ (1999) Structure and function of the CFTR chloride channel. Physiol Rev 79(1 Suppl):S23-45. https:\/\/doi.org\/10.1152\/physrev.1999.79.1.S23","journal-title":"Physiol Rev"},{"key":"4030_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fphar.2019.00121","volume":"10","author":"I Pranke","year":"2019","unstructured":"Pranke I, Golec A, Hinzpeter A, Edelman A, Sermet-Gaudelus I (2019) Emerging therapeutic approaches for cystic fibrosis. From gene editing to personalized medicine. Front Pharmacol 10:121. https:\/\/doi.org\/10.3389\/fphar.2019.00121","journal-title":"Front Pharmacol"},{"issue":"4922","key":"4030_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1126\/science.2475911","volume":"245","author":"JR Riordan","year":"1989","unstructured":"Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL et al (1989) Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245(4922):1066\u20131073. https:\/\/doi.org\/10.1126\/science.2475911","journal-title":"Science"},{"issue":"5","key":"4030_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/0092-8674(91)90446-6","volume":"66","author":"SH Cheng","year":"1991","unstructured":"Cheng SH, Rich DP, Marshall J, Gregory RJ, Welsh MJ, Smith AE (1991) Phosphorylation of the R domain by cAMP-dependent protein kinase regulates the CFTR chloride channel. Cell 66(5):1027\u20131036. https:\/\/doi.org\/10.1016\/0092-8674(91)90446-6","journal-title":"Cell"},{"issue":"5077","key":"4030_CR8","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1126\/science.1382316","volume":"257","author":"MP Anderson","year":"1992","unstructured":"Anderson MP, Welsh MJ (1992) Regulation by ATP and ADP of CFTR chloride channels that contain mutant nucleotide-binding domains. Science 257(5077):1701\u20131704. https:\/\/doi.org\/10.1126\/science.1382316","journal-title":"Science"},{"issue":"21","key":"4030_CR9","doi-asserted-by":"publisher","first-page":"9963","DOI":"10.1073\/pnas.90.21.9963","volume":"90","author":"LS Smit","year":"1993","unstructured":"Smit LS, Wilkinson DJ, Mansoura MK, Collins FS, Dawson DC (1993) Functional roles of the nucleotide-binding folds in the activation of the cystic fibrosis transmembrane conductance regulator. Proc Natl Acad Sci USA 90(21):9963\u20139967. https:\/\/doi.org\/10.1073\/pnas.90.21.9963","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"4030_CR10","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1074\/jbc.270.4.1711","volume":"270","author":"MR Carson","year":"1995","unstructured":"Carson MR, Travis SM, Welsh MJ (1995) The two nucleotide-binding domains of cystic fibrosis transmembrane conductance regulator (CFTR) have distinct functions in controlling channel activity. J Biol Chem 270(4):1711\u20131717. https:\/\/doi.org\/10.1074\/jbc.270.4.1711","journal-title":"J Biol Chem"},{"issue":"1","key":"4030_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0092-8674(95)90241-4","volume":"83","author":"TJ Jensen","year":"1995","unstructured":"Jensen TJ, Loo MA, Pind S, Williams DB, Goldberg AL, Riordan JR (1995) Multiple proteolytic systems, including the proteasome, contribute to CFTR processing. Cell 83(1):129\u2013135. https:\/\/doi.org\/10.1016\/0092-8674(95)90241-4","journal-title":"Cell"},{"key":"4030_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.biocel.2014.03.020","volume":"52","author":"IM Pranke","year":"2014","unstructured":"Pranke IM, Sermet-Gaudelus I (2014) Biosynthesis of cystic fibrosis transmembrane conductance regulator. Int J Biochem Cell Biol 52:26\u201338. https:\/\/doi.org\/10.1016\/j.biocel.2014.03.020","journal-title":"Int J Biochem Cell Biol"},{"issue":"6389","key":"4030_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/358761a0","volume":"358","author":"GM Denning","year":"1992","unstructured":"Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ (1992) Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358(6389):761\u2013764. https:\/\/doi.org\/10.1038\/358761a0","journal-title":"Nature"},{"issue":"11","key":"4030_CR14","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.2217\/fmb.10.125","volume":"5","author":"N Hoiby","year":"2010","unstructured":"Hoiby N, Ciofu O, Bjarnsholt T (2010) Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol 5(11):1663\u20131674. https:\/\/doi.org\/10.2217\/fmb.10.125","journal-title":"Future Microbiol"},{"issue":"6354","key":"4030_CR15","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/354526a0","volume":"354","author":"W Dalemans","year":"1991","unstructured":"Dalemans W, Barbry P, Champigny G, Jallat S, Dott K, Dreyer D, Crystal RG, Pavirani A, Lecocq JP, Lazdunski M (1991) Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation. Nature 354(6354):526\u2013528. https:\/\/doi.org\/10.1038\/354526a0","journal-title":"Nature"},{"issue":"10","key":"4030_CR16","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/emmm.201302699","volume":"5","author":"N Odolczyk","year":"2013","unstructured":"Odolczyk N, Fritsch J, Norez C, Servel N, da Cunha MF, Bitam S, Kupniewska A, Wiszniewski L, Colas J, Tarnowski K, Tondelier D, Roldan A, Saussereau EL, Melin-Heschel P, Wieczorek G, Lukacs GL, Dadlez M, Faure G, Herrmann H, Ollero M, Becq F, Zielenkiewicz P, Edelman A (2013) Discovery of novel potent DeltaF508-CFTR correctors that target the nucleotide binding domain. EMBO Mol Med 5(10):1484\u20131501. https:\/\/doi.org\/10.1002\/emmm.201302699","journal-title":"EMBO Mol Med"},{"issue":"8","key":"4030_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","volume":"4","author":"JS Elborn","year":"2016","unstructured":"Elborn JS, Ramsey BW, Boyle MP, Konstan MW, Huang X, Marigowda G, Waltz D, Wainwright CE, Vx T, groups Ts, (2016) Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. Lancet Respir Med 4(8):617","journal-title":"Lancet Respir Med"},{"issue":"17","key":"4030_CR18","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1807119","volume":"379","author":"JC Davies","year":"2018","unstructured":"Davies JC, Moskowitz SM, Brown C, Horsley A, Mall MA, McKone EF, Plant BJ, Prais D, Ramsey BW, Taylor-Cousar JL, Tullis E, Uluer A, McKee CM, Robertson S, Shilling RA, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Rowe SM, Group VXS (2018) VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379(17):1599\u20131611. https:\/\/doi.org\/10.1056\/NEJMoa1807119","journal-title":"N Engl J Med"},{"issue":"17","key":"4030_CR19","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating D, Marigowda G, Burr L, Daines C, Mall MA, McKone EF, Ramsey BW, Rowe SM, Sass LA, Tullis E, McKee CM, Moskowitz SM, Robertson S, Savage J, Simard C, Van Goor F, Waltz D, Xuan F, Young T, Taylor-Cousar JL, Group VXS (2018) VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Engl J Med 379(17):1612\u20131620. https:\/\/doi.org\/10.1056\/NEJMoa1807120","journal-title":"N Engl J Med"},{"issue":"7","key":"4030_CR20","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/pharmaceutics12070616","volume":"12","author":"FA Almughem","year":"2020","unstructured":"Almughem FA, Aldossary AM, Tawfik EA, Alomary MN, Alharbi WS, Alshahrani MY, Alshehri AA (2020) Cystic fibrosis: overview of the current development trends and innovative therapeutic strategies. Pharmaceutics 12(7):616. https:\/\/doi.org\/10.3390\/pharmaceutics12070616","journal-title":"Pharmaceutics"},{"key":"4030_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3389\/fcimb.2016.00194","volume":"6","author":"M Mahlapuu","year":"2016","unstructured":"Mahlapuu M, Hakansson J, Ringstad L, Bjorn C (2016) Antimicrobial peptides: an emerging category of therapeutic agents. Front Cell Infect Microbiol 6:194. https:\/\/doi.org\/10.3389\/fcimb.2016.00194","journal-title":"Front Cell Infect Microbiol"},{"issue":"7","key":"4030_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1080\/07388551.2020.1796576","volume":"40","author":"M Mahlapuu","year":"2020","unstructured":"Mahlapuu M, Bjorn C, Ekblom J (2020) Antimicrobial peptides as therapeutic agents: opportunities and challenges. Crit Rev Biotechnol 40(7):978\u2013992. https:\/\/doi.org\/10.1080\/07388551.2020.1796576","journal-title":"Crit Rev Biotechnol"},{"key":"4030_CR23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fnins.2017.00073","volume":"11","author":"J Li","year":"2017","unstructured":"Li J, Koh JJ, Liu S, Lakshminarayanan R, Verma CS, Beuerman RW (2017) Membrane active antimicrobial peptides: translating mechanistic insights to design. Front Neurosci 11:73. https:\/\/doi.org\/10.3389\/fnins.2017.00073","journal-title":"Front Neurosci"},{"issue":"9","key":"4030_CR24","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/psc.1148","volume":"15","author":"AE Islas-Rodriguez","year":"2009","unstructured":"Islas-Rodriguez AE, Marcellini L, Orioni B, Barra D, Stella L, Mangoni ML (2009) Esculentin 1\u201321: a linear antimicrobial peptide from frog skin with inhibitory effect on bovine mastitis-causing bacteria. J Pept Sci 15(9):607\u2013614. https:\/\/doi.org\/10.1002\/psc.1148","journal-title":"J Pept Sci"},{"issue":"15","key":"4030_CR25","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1007\/s00018-013-1291-7","volume":"70","author":"V Luca","year":"2013","unstructured":"Luca V, Stringaro A, Colone M, Pini A, Mangoni ML (2013) Esculentin(1\u201321), an amphibian skin membrane-active peptide with potent activity on both planktonic and biofilm cells of the bacterial pathogen Pseudomonas aeruginosa. Cell Mol Life Sci 70(15):2773\u20132786. https:\/\/doi.org\/10.1007\/s00018-013-1291-7","journal-title":"Cell Mol Life Sci"},{"issue":"12","key":"4030_CR26","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1128\/AAC.00904-16","volume":"60","author":"F Cappiello","year":"2016","unstructured":"Cappiello F, Di Grazia A, Segev-Zarko LA, Scali S, Ferrera L, Galietta L, Pini A, Shai Y, Di YP, Mangoni ML (2016) Esculentin-1a-derived peptides promote clearance of pseudomonas aeruginosa internalized in bronchial cells of cystic fibrosis patients and lung cell migration: biochemical properties and a plausible mode of action. Antimicrob Agents Chemother 60(12):7252\u20137262. https:\/\/doi.org\/10.1128\/AAC.00904-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4030_CR27","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1128\/IAI.73.1.583-591.2005","volume":"73","author":"YE Lau","year":"2005","unstructured":"Lau YE, Rozek A, Scott MG, Goosney DL, Davidson DJ, Hancock RE (2005) Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect Immun 73(1):583\u2013591. https:\/\/doi.org\/10.1128\/IAI.73.1.583-591.2005","journal-title":"Infect Immun"},{"issue":"12","key":"4030_CR28","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1007\/s00726-015-2041-y","volume":"47","author":"A Di Grazia","year":"2015","unstructured":"Di Grazia A, Cappiello F, Cohen H, Casciaro B, Luca V, Pini A, Di YP, Shai Y, Mangoni ML (2015) D-Amino acids incorporation in the frog skin-derived peptide esculentin-1a(1\u201321)NH2 is beneficial for its multiple functions. Amino Acids 47(12):2505\u20132519. https:\/\/doi.org\/10.1007\/s00726-015-2041-y","journal-title":"Amino Acids"},{"key":"4030_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fchem.2017.00026","volume":"5","author":"B Casciaro","year":"2017","unstructured":"Casciaro B, Cappiello F, Cacciafesta M, Mangoni ML (2017) Promising approaches to optimize the biological properties of the antimicrobial peptide esculentin-1a(1\u201321)NH2: amino acids substitution and conjugation to nanoparticles. Front Chem 5:26. https:\/\/doi.org\/10.3389\/fchem.2017.00026","journal-title":"Front Chem"},{"issue":"1","key":"4030_CR30","doi-asserted-by":"publisher","first-page":"8548","DOI":"10.1038\/s41598-017-08361-8","volume":"7","author":"C Chen","year":"2017","unstructured":"Chen C, Mangoni ML, Di YP (2017) In vivo therapeutic efficacy of frog skin-derived peptides against Pseudomonas aeruginosa-induced pulmonary infection. Sci Rep 7(1):8548. https:\/\/doi.org\/10.1038\/s41598-017-08361-8","journal-title":"Sci Rep"},{"issue":"2","key":"4030_CR31","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2211068214561025","volume":"20","author":"B Srinivasan","year":"2015","unstructured":"Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ (2015) TEER measurement techniques for in vitro barrier model systems. J Lab Autom 20(2):107\u2013126. https:\/\/doi.org\/10.1177\/2211068214561025","journal-title":"J Lab Autom"},{"issue":"3","key":"4030_CR32","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jcf.2015.11.010","volume":"15","author":"LB Gottschalk","year":"2016","unstructured":"Gottschalk LB, Vecchio-Pagan B, Sharma N, Han ST, Franca A, Wohler ES, Batista DA, Goff LA, Cutting GR (2016) Creation and characterization of an airway epithelial cell line for stable expression of CFTR variants. J Cyst Fibros 15(3):285\u2013294. https:\/\/doi.org\/10.1016\/j.jcf.2015.11.010","journal-title":"J Cyst Fibros"},{"issue":"4","key":"4030_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.pupt.2010.02.001","volume":"23","author":"SM Rowe","year":"2010","unstructured":"Rowe SM, Pyle LC, Jurkevante A, Varga K, Collawn J, Sloane PA, Woodworth B, Mazur M, Fulton J, Fan L, Li Y, Fortenberry J, Sorscher EJ, Clancy JP (2010) DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 23(4):268\u2013278. https:\/\/doi.org\/10.1016\/j.pupt.2010.02.001","journal-title":"Pulm Pharmacol Ther"},{"issue":"7","key":"4030_CR34","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1016\/0092-8674(93)90353-r","volume":"73","author":"MJ Welsh","year":"1993","unstructured":"Welsh MJ, Smith AE (1993) Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73(7):1251\u20131254. https:\/\/doi.org\/10.1016\/0092-8674(93)90353-r","journal-title":"Cell"},{"key":"4030_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejps.2014.12.017","volume":"69","author":"ME Kreft","year":"2015","unstructured":"Kreft ME, Jerman UD, Lasic E, Hevir-Kene N, Rizner TL, Peternel L, Kristan K (2015) The characterization of the human cell line Calu-3 under different culture conditions and its use as an optimized in vitro model to investigate bronchial epithelial function. Eur J Pharm Sci 69:1\u20139. https:\/\/doi.org\/10.1016\/j.ejps.2014.12.017","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"4030_CR36","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1172\/JCI16112","volume":"110","author":"T Ma","year":"2002","unstructured":"Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galietta LJ, Verkman AS (2002) Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. J Clin Invest 110(11):1651\u20131658. https:\/\/doi.org\/10.1172\/JCI16112","journal-title":"J Clin Invest"},{"issue":"6","key":"4030_CR37","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/sj.bjp.0707663","volume":"153","author":"A Schmidt","year":"2008","unstructured":"Schmidt A, Hughes LK, Cai Z, Mendes F, Li H, Sheppard DN, Amaral MD (2008) Prolonged treatment of cells with genistein modulates the expression and function of the cystic fibrosis transmembrane conductance regulator. Br J Pharmacol 153(6):1311\u20131323. https:\/\/doi.org\/10.1038\/sj.bjp.0707663","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4030_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s004240050424","volume":"434","author":"F Weinreich","year":"1997","unstructured":"Weinreich F, Wood PG, Riordan JR, Nagel G (1997) Direct action of genistein on CFTR. Pflugers Arch 434(4):484\u2013491. https:\/\/doi.org\/10.1007\/s004240050424","journal-title":"Pflugers Arch"},{"issue":"1 Pt 1","key":"4030_CR39","doi-asserted-by":"publisher","first-page":"C265","DOI":"10.1152\/ajpcell.1996","volume":"270","author":"B Illek","year":"1996","unstructured":"Illek B, Fischer H, Machen TE (1996) Alternate stimulation of apical CFTR by genistein in epithelia. Am J Physiol 270(1 Pt 1):C265-275. https:\/\/doi.org\/10.1152\/ajpcell.1996","journal-title":"Am J Physiol"},{"issue":"12","key":"4030_CR40","doi-asserted-by":"publisher","first-page":"6127","DOI":"10.1021\/acs.jctc.8b00391","volume":"14","author":"B Knapp","year":"2018","unstructured":"Knapp B, Ospina L, Deane CM (2018) Avoiding false positive conclusions in molecular simulation: the importance of replicas. J Chem Theory Comput 14(12):6127\u20136138. https:\/\/doi.org\/10.1021\/acs.jctc.8b00391","journal-title":"J Chem Theory Comput"},{"issue":"9","key":"4030_CR41","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","volume":"8","author":"BR Miller","year":"2012","unstructured":"Miller BR, McGee TD, Swails JM, Homeyer N, Gohlke H, Roitberg AE (2012) MMPBSA.py: an efficient program for end-state free energy calculations. J Chem Theory Comput 8(9):3314\u20133321. https:\/\/doi.org\/10.1021\/ct300418h","journal-title":"J Chem Theory Comput"},{"issue":"9678","key":"4030_CR42","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan BP, Freedman SD (2009) Cystic fibrosis. Lancet 373(9678):1891\u20131904. https:\/\/doi.org\/10.1016\/S0140-6736(09)60327-5","journal-title":"Lancet"},{"key":"4030_CR43","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","volume":"1","author":"F Ratjen","year":"2015","unstructured":"Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A (2015) Cystic fibrosis. Nat Rev Dis Primers 1:15010. https:\/\/doi.org\/10.1038\/nrdp.2015.10","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 3","key":"4030_CR44","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1002\/ppul.24522","volume":"54","author":"L Saiman","year":"2019","unstructured":"Saiman L (2019) Improving outcomes of infections in cystic fibrosis in the era of CFTR modulator therapy. Pediatr Pulmonol 54(Suppl 3):S18\u2013S26. https:\/\/doi.org\/10.1002\/ppul.24522","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"4030_CR45","doi-asserted-by":"publisher","first-page":"200016","DOI":"10.1183\/20734735.0016-2020","volume":"16","author":"S Cuevas-Ocana","year":"2020","unstructured":"Cuevas-Ocana S, Laselva O, Avolio J, Nenna R (2020) The era of CFTR modulators: improvements made and remaining challenges. Breathe (Sheff) 16(2):200016. https:\/\/doi.org\/10.1183\/20734735.0016-2020","journal-title":"Breathe (Sheff)"},{"issue":"2 Pt 1","key":"4030_CR46","doi-asserted-by":"publisher","first-page":"C747","DOI":"10.1152\/ajpcell.1997.273.2.C747","volume":"273","author":"PJ French","year":"1997","unstructured":"French PJ, Bijman J, Bot AG, Boomaars WE, Scholte BJ, de Jonge HR (1997) Genistein activates CFTR Cl- channels via a tyrosine kinase- and protein phosphatase-independent mechanism. Am J Physiol 273(2 Pt 1):C747-753. https:\/\/doi.org\/10.1152\/ajpcell.1997.273.2.C747","journal-title":"Am J Physiol"},{"issue":"3","key":"4030_CR47","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1085\/jgp.111.3.477","volume":"111","author":"F Wang","year":"1998","unstructured":"Wang F, Zeltwanger S, Yang IC, Nairn AC, Hwang TC (1998) Actions of genistein on cystic fibrosis transmembrane conductance regulator channel gating. Evidence for two binding sites with opposite effects. J Gen Physiol 111(3):477\u2013490. https:\/\/doi.org\/10.1085\/jgp.111.3.477","journal-title":"J Gen Physiol"},{"issue":"21","key":"4030_CR48","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","volume":"377","author":"JL Taylor-Cousar","year":"2017","unstructured":"Taylor-Cousar JL, Munck A, McKone EF, van der Ent CK, Moeller A, Simard C, Wang LT, Ingenito EP, McKee C, Lu Y, Lekstrom-Himes J, Elborn JS (2017) Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Engl J Med 377(21):2013\u20132023. https:\/\/doi.org\/10.1056\/NEJMoa1709846","journal-title":"N Engl J Med"},{"issue":"12","key":"4030_CR49","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1085\/jgp.201711886","volume":"149","author":"HI Yeh","year":"2017","unstructured":"Yeh HI, Sohma Y, Conrath K, Hwang TC (2017) A common mechanism for CFTR potentiators. J Gen Physiol 149(12):1105","journal-title":"J Gen Physiol"},{"issue":"18","key":"4030_CR50","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","volume":"365","author":"BW Ramsey","year":"2011","unstructured":"Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS, Group VXS (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 365(18):1663\u20131672. https:\/\/doi.org\/10.1056\/NEJMoa1105185","journal-title":"N Engl J Med"},{"key":"4030_CR51","doi-asserted-by":"publisher","first-page":"113195","DOI":"10.1016\/j.ejmech.2021.113195","volume":"213","author":"E Bardin","year":"2021","unstructured":"Bardin E, Pastor A, Semeraro M, Golec A, Hayes K, Chevalier B, Berhal F, Prestat G, Hinzpeter A, Gravier-Pelletier C, Pranke I, Sermet-Gaudelus I (2021) Modulators of CFTR. Updates on clinical development and future directions. Eur J Med Chem 213:113195. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113195","journal-title":"Eur J Med Chem"},{"key":"4030_CR52","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.3389\/fphar.2018.01221","volume":"9","author":"M Gees","year":"2018","unstructured":"Gees M, Musch S, Van der Plas S, Wesse AS, Vandevelde A, Verdonck K, Mammoliti O, Hwang TC, Sonck K, Stouten P, Swensen AM, Jans M, Van der Schueren J, Nelles L, Andrews M, Conrath K (2018) Identification and Characterization of novel CFTR potentiators. Front Pharmacol 9:1221. https:\/\/doi.org\/10.3389\/fphar.2018.01221","journal-title":"Front Pharmacol"},{"issue":"1","key":"4030_CR53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1021\/acs.jmedchem.0c01796","volume":"64","author":"SE Van der Plas","year":"2021","unstructured":"Van der Plas SE, Kelgtermans H, Mammoliti O, Menet C, Tricarico G, De Blieck A, Joannesse C, De Munck T, Lambin D, Cowart M, Dropsit S, Martina SLX, Gees M, Wesse AS, Conrath K, Andrews M (2021) Discovery of GLPG2451, a novel once daily potentiator for the treatment of cystic fibrosis. J Med Chem 64(1):343\u2013353. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01796","journal-title":"J Med Chem"},{"issue":"1","key":"4030_CR54","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/17476348.2020.1682998","volume":"14","author":"SL Paterson","year":"2020","unstructured":"Paterson SL, Barry PJ, Horsley AR (2020) Tezacaftor and ivacaftor for the treatment of cystic fibrosis. Expert Rev Respir Med 14(1):15\u201330. https:\/\/doi.org\/10.1080\/17476348.2020.1682998","journal-title":"Expert Rev Respir Med"},{"issue":"6","key":"4030_CR55","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1183\/09031936.00221711","volume":"40","author":"NT Trinh","year":"2012","unstructured":"Trinh NT, Bardou O, Prive A, Maille E, Adam D, Lingee S, Ferraro P, Desrosiers MY, Coraux C, Brochiero E (2012) Improvement of defective cystic fibrosis airway epithelial wound repair after CFTR rescue. Eur Respir J 40(6):1390\u20131400. https:\/\/doi.org\/10.1183\/09031936.00221711","journal-title":"Eur Respir J"},{"issue":"5","key":"4030_CR56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","volume":"19","author":"N Mookherjee","year":"2020","unstructured":"Mookherjee N, Anderson MA, Haagsman HP, Davidson DJ (2020) Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov 19(5):311\u2013332. https:\/\/doi.org\/10.1038\/s41573-019-0058-8","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4030_CR57","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1096\/fj.201901896RR","volume":"34","author":"L Quercini","year":"2020","unstructured":"Quercini L, Brunetti J, Riolo G, Bindi S, Scali S, Lampronti I, D\u2019Aversa E, Wronski S, Pollini S, Gentile M, Lupetti P, Rossolini GM, Falciani C, Bracci L, Pini A (2020) An antimicrobial molecule mitigates signs of sepsis in vivo and eradicates infections from lung tissue. FASEB J 34(1):192\u2013207. https:\/\/doi.org\/10.1096\/fj.201901896RR","journal-title":"FASEB J"},{"issue":"5","key":"4030_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/pep2.24122","volume":"111","author":"JS Hye Been Koo","year":"2019","unstructured":"Hye Been Koo JS (2019) Antimicrobial peptides under clinical investigation. Pept Sci 111(5):e24122. https:\/\/doi.org\/10.1002\/pep2.24122","journal-title":"Pept Sci"},{"issue":"4","key":"4030_CR59","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/14787210.2018.1441024","volume":"16","author":"I Martin-Loeches","year":"2018","unstructured":"Martin-Loeches I, Dale GE, Torres A (2018) Murepavadin: a new antibiotic class in the pipeline. Expert Rev Anti Infect Ther 16(4):259\u2013268. https:\/\/doi.org\/10.1080\/14787210.2018.1441024","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"4030_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1872213X12666181012101444","volume":"13","author":"V Sala","year":"2019","unstructured":"Sala V, Murabito A, Ghigo A (2019) Inhaled biologicals for the treatment of cystic fibrosis. Recent Pat Inflamm Allergy Drug Discov 13(1):19\u201326. https:\/\/doi.org\/10.2174\/1872213X12666181012101444","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"issue":"5","key":"4030_CR61","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1021\/acs.biomac.8b01829","volume":"20","author":"B Casciaro","year":"2019","unstructured":"Casciaro B, d\u2019Angelo I, Zhang X, Loffredo MR, Conte G, Cappiello F, Quaglia F, Di YP, Ungaro F, Mangoni ML (2019) Poly(lactide- co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against pseudomonas aeruginosa lung infection: in vitro and in vivo studies. Biomacromol 20(5):1876\u20131888. https:\/\/doi.org\/10.1021\/acs.biomac.8b01829","journal-title":"Biomacromol"},{"key":"4030_CR62","doi-asserted-by":"publisher","first-page":"104714","DOI":"10.1016\/j.tiv.2019.104714","volume":"63","author":"D Ritter","year":"2020","unstructured":"Ritter D, Knebel J, Niehof M, Loinaz I, Marradi M, Gracia R, Te Welscher Y, van Nostrum CF, Falciani C, Pini A, Strandh M, Hansen T (2020) In vitro inhalation cytotoxicity testing of therapeutic nanosystems for pulmonary infection. Toxicol In Vitro 63:104714. https:\/\/doi.org\/10.1016\/j.tiv.2019.104714","journal-title":"Toxicol In Vitro"},{"key":"4030_CR63","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2147\/IJN.S218966","volume":"15","author":"C Falciani","year":"2020","unstructured":"Falciani C, Zevolini F, Brunetti J, Riolo G, Gracia R, Marradi M, Loinaz I, Ziemann C, Cossio U, Llop J, Bracci L, Pini A (2020) Antimicrobial peptide-loaded nanoparticles as inhalation therapy for pseudomonas aeruginosa infections. Int J Nanomed 15:1117\u20131128. https:\/\/doi.org\/10.2147\/IJN.S218966","journal-title":"Int J Nanomed"},{"issue":"5","key":"4030_CR64","doi-asserted-by":"publisher","first-page":"C912","DOI":"10.1152\/ajpcell.00215.2010","volume":"299","author":"KR Schiller","year":"2010","unstructured":"Schiller KR, Maniak PJ, O\u2019Grady SM (2010) Cystic fibrosis transmembrane conductance regulator is involved in airway epithelial wound repair. Am J Physiol Cell Physiol 299(5):C912-921. https:\/\/doi.org\/10.1152\/ajpcell.00215.2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"4030_CR65","doi-asserted-by":"publisher","first-page":"L866","DOI":"10.1152\/ajplung.90224.2008","volume":"295","author":"NT Trinh","year":"2008","unstructured":"Trinh NT, Prive A, Maille E, Noel J, Brochiero E (2008) EGF and K+ channel activity control normal and cystic fibrosis bronchial epithelia repair. Am J Physiol Lung Cell Mol Physiol 295(5):L866-880. https:\/\/doi.org\/10.1152\/ajplung.90224.2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"4","key":"4030_CR66","doi-asserted-by":"publisher","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","volume":"301","author":"E Sondo","year":"2011","unstructured":"Sondo E, Tomati V, Caci E, Esposito AI, Pfeffer U, Pedemonte N, Galietta LJ (2011) Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 301(4):C872-885. https:\/\/doi.org\/10.1152\/ajpcell.00507.2010","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"4030_CR67","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.chembiol.2018.04.010","volume":"25","author":"E Sondo","year":"2018","unstructured":"Sondo E, Falchi F, Caci E, Ferrera L, Giacomini E, Pesce E, Tomati V, Mandrup Bertozzi S, Goldoni L, Armirotti A, Ravazzolo R, Cavalli A, Pedemonte N (2018) Pharmacological inhibition of the ubiquitin ligase RNF5 rescues F508del-CFTR in cystic fibrosis airway epithelia. Cell Chem Biol 25(7):891-905 e8. https:\/\/doi.org\/10.1016\/j.chembiol.2018.04.010","journal-title":"Cell Chem Biol"},{"issue":"23","key":"4030_CR68","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1113\/jphysiol.2012.240838","volume":"590","author":"P Scudieri","year":"2012","unstructured":"Scudieri P, Caci E, Bruno S, Ferrera L, Schiavon M, Sondo E, Tomati V, Gianotti A, Zegarra-Moran O, Pedemonte N, Rea F, Ravazzolo R, Galietta LJ (2012) Association of TMEM16A chloride channel overexpression with airway goblet cell metaplasia. J Physiol 590(23):6141\u20136155. https:\/\/doi.org\/10.1113\/jphysiol.2012.240838","journal-title":"J Physiol"},{"issue":"3","key":"4030_CR69","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98699","volume":"3","author":"V Tomati","year":"2018","unstructured":"Tomati V, Caci E, Ferrera L, Pesce E, Sondo E, Cholon DM, Quinney NL, Boyles SE, Armirotti A, Ravazzolo R, Galietta LJ, Gentzsch M, Pedemonte N (2018) Thymosin alpha-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia. JCI Insight 3(3):e98699. https:\/\/doi.org\/10.1172\/jci.insight.98699","journal-title":"JCI Insight"},{"issue":"2","key":"4030_CR70","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/prot.10613","volume":"55","author":"MP Jacobson","year":"2004","unstructured":"Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins 55(2):351\u2013367. https:\/\/doi.org\/10.1002\/prot.10613","journal-title":"Proteins"},{"issue":"50","key":"4030_CR71","doi-asserted-by":"publisher","first-page":"12757","DOI":"10.1073\/pnas.1815287115","volume":"115","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Liu F, Chen J (2018) Molecular structure of the ATP-bound, phosphorylated human CFTR. Proc Natl Acad Sci USA 115(50):12757\u201312762. https:\/\/doi.org\/10.1073\/pnas.1815287115","journal-title":"Proc Natl Acad Sci USA"},{"key":"4030_CR72","doi-asserted-by":"publisher","first-page":"W537","DOI":"10.1093\/nar\/gks375","volume":"40","author":"R Anandakrishnan","year":"2012","unstructured":"Anandakrishnan R, Aguilar B, Onufriev AV (2012) H++ 3.0: automating pK prediction and the preparation of biomolecular structures for atomistic molecular modeling and simulations. Nucleic Acids Res 40:W537-541. https:\/\/doi.org\/10.1093\/nar\/gks375","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"4030_CR73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","volume":"3","author":"RC Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer RC, Case DA, Walker RC (2013) An overview of the Amberbiomolecular simulation package. WIREs Comput Mol Sci 3(2):198\u2013210. https:\/\/doi.org\/10.1002\/wcms.1121","journal-title":"WIREs Comput Mol Sci"},{"key":"4030_CR74","unstructured":"Case DA, Ben-Shalom IY, Brozell SR, Cerutti DS, Cheatham TE III, Cruzeiro VWD, Darden TA, Duke RE, Ghoreishi D, Gilson MK, Gohlke H, Goetz AW, Greene D, Harris R, Homeyer N, Huang Y, Izadi S, Kovalenko A, Kurtzman T, Lee TS, LeGrand S, Li P, Lin C, Liu J, Luchko T, Luo R, Mermelstein DJ, Merz KM, Miao Y, Monard G, Nguyen C, Nguyen H, Omelyan I, Onufriev A, Pan F, Qi R, Roe DR, Roitberg A, Sagui C, Schott-Verdugo S, Shen J, Simmerling CL, Smith J, Salomon-Ferrer R, Swails J, Walker RC, Wang J, Wei H, Wolf RM, Wu X, Xiao L, York DM and Kollman PA (2018) AMBER 2018 University of California, San Francisco. https:\/\/ambermd.org\/doc12\/Amber18.pdf"},{"issue":"9","key":"4030_CR75","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25(9):1157\u20131174. https:\/\/doi.org\/10.1002\/jcc.20035","journal-title":"J Comput Chem"},{"issue":"7","key":"4030_CR76","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1021\/ct400341p","volume":"9","author":"DR Roe","year":"2013","unstructured":"Roe DR, Cheatham TE 3rd (2013) PTRAJ and CPPTRAJ: Software for processing and analysis of molecular dynamics trajectory data. J Chem Theory Comput 9(7):3084\u20133095. https:\/\/doi.org\/10.1021\/ct400341p","journal-title":"J Chem Theory Comput"},{"key":"4030_CR77","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1016\/j.bbamem.2017.09.009","volume":"12","author":"MR Loffredo","year":"1859","unstructured":"Loffredo MR, Ghosh A, Harmouche N, Casciaro B, Luca V, Bortolotti A, Cappiello F, Stella L, Bhunia A, Bechinger B (1859) Mangoni ML (2017) Membrane perturbing activities and structural properties of the frog-skin derived peptide Esculentin-1a(1\u201321)NH2 and its Diastereomer Esc(1\u201321)-1c: Correlation with their antipseudomonal and cytotoxic activity. Biochim Biophys Acta 12:2327\u20132339. https:\/\/doi.org\/10.1016\/j.bbamem.2017.09.009","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"4030_CR78","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00894-005-0028-4","volume":"12","author":"N Homeyer","year":"2006","unstructured":"Homeyer N, Horn AH, Lanig H, Sticht H (2006) AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model 12(3):281\u2013289. https:\/\/doi.org\/10.1007\/s00894-005-0028-4","journal-title":"J Mol Model"},{"issue":"12","key":"4030_CR79","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.1021\/acs.jcim.0c00722","volume":"60","author":"A Ballone","year":"2020","unstructured":"Ballone A, Picarazzi F, Prosser C, Davis J, Ottmann C, Mori M (2020) Experimental and computational druggability exploration of the 14\u20133\u20133zeta\/SOS1pS(1161) PPI interface. J Chem Inf Model 60(12):6555\u20136565. https:\/\/doi.org\/10.1021\/acs.jcim.0c00722","journal-title":"J Chem Inf Model"},{"issue":"18","key":"4030_CR80","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.1073\/pnas.181342398","volume":"98","author":"NA Baker","year":"2001","unstructured":"Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA (2001) Electrostatics of nanosystems: application to microtubules and the ribosome. Proc Natl Acad Sci USA 98(18):10037\u201310041. https:\/\/doi.org\/10.1073\/pnas.181342398","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-04030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-021-04030-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-021-04030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T02:17:33Z","timestamp":1645669053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-021-04030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,31]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["4030"],"URL":"https:\/\/doi.org\/10.1007\/s00018-021-04030-2","relation":{},"ISSN":["1420-682X","1420-9071"],"issn-type":[{"value":"1420-682X","type":"print"},{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,31]]},"assertion":[{"value":"25 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study on bronchial cells to investigate the effect of the peptides on CFTR was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of the IRCCS Istituto Giannina Gaslini, Genova (24 September 2010; Number: 182). Informed consent to participate in scientific studies and to publish data in research journal articles was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agreed with the content of the article and approved its submission for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"67"}}